Citius Oncology reported fiscal third quarter results ending June 30, 2026, generating $1.5 million in revenue for the quarter and $7.1 million for the first nine months of fiscal 2026, compared to zero in the prior year period. The company recorded a net loss of $8.9 million, or $(0.08) per share, for the quarter, driven by a $30.7 million general and administrative expense total that included a $19.7 million one-time CMO contract cancellation charge. Cash and cash equivalents stood at $16.6 million as of June 30, 2026, following approximately $9.7 million in net proceeds from warrant exercises and the funding of a $10.0 million tranche under a senior secured term loan facility. Institutional demand for its product LYMPHIR accelerated, with vial orders growing 31% sequentially to 926 units and 44 institutions now ordering the therapy. Citius Oncology is an oncology-focused biopharmaceutical company developing and commercializing targeted therapies.

Citius Oncology, Inc. announced the appointment of Jonathan Peri, Ph.D., J.D., as an independent Class I director to its Board of Directors, effective August 10, 2026. The Board expanded from eight to nine members following a unanimous vote by the Corporate Governance and Nominating Committee. Dr. Peri currently serves as President of Manor College and previously held leadership roles at Neumann University and First State Bank. He brings expertise in higher education administration, legal counsel, and corporate governance. Citius Oncology is an oncology-focused biopharmaceutical company developing and commercializing targeted therapies for cutaneous T-cell lymphoma.